ESC 365 - Doctor John Ostrominski

Speaker illustration

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials

Event: Heart Failure 2025

Topic: Renal Failure and Cardiovascular Disease

Session: ePosters in cardiovascular disease in special populations (3)

The HFpEF-ABA, H2FPEF, and HFA-PEFF scores and outcomes in individuals with HFpEF: a participant-level pooled analysis of 5 large-scale randomized clinical trials

Event: Heart Failure 2025

Topic: Diagnostic Methods

Session: Late-breaking science: diagnostic methods and assessment

Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart failure with preserved ejection fraction (HFpEF) 3

Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure - epidemiology, prognosis, outcome 2

Cardio-renal-metabolic overlap, outcomes, and treatment with dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

Event: Heart Failure 2023

Topic: Comorbidities

Session: Chronic heart failure - comorbidities

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources